胆红素纳米颗粒的药理作用研究进展

乔婷婷; 张志宏; 周俊发; 叶仕高; 曾元宁; 王秋红

doi:10.6039/j.issn.1001-0408.2023.05.22

您当前的位置：

首页 >

文章列表页 >

胆红素纳米颗粒的药理作用研究进展

综述 | 更新时间：2023-06-12

- 胆红素纳米颗粒的药理作用研究进展
- Research progress on pharmacological effects of bilirubin nanoparticles
- 中国药房 2023年34卷第5期页码：631-635
- 作者机构：
  
  1.广东药科大学中药学院/广东省中药饮片规范化炮制工程技术研究中心，广州　510006
  2.黑龙江中医药大学教育部北药基础与应用研究重点实验室，哈尔滨　150040
- 作者简介：
  
  硕士研究生。研究方向：中药炮制、中药药效物质基础和作用机制。E-mail：qiaott025@163.com
  教授，博士生导师，博士。研究方向：中药炮制、中药药效物质基础和作用机制。电话：020-39353241。E-mail：qhwang668 @sina.com
- 基金信息：
  
  广东省重点领域研发计划项目(2020B111112-0002)
- DOI：10.6039/j.issn.1001-0408.2023.05.22
  中图分类号： R965;R283.6
- 纸质出版日期：2023-03-15，
  
  收稿日期：2022-08-31，
  
  修回日期：2023-02-03，
扫描看全文
乔婷婷,张志宏,周俊发等.胆红素纳米颗粒的药理作用研究进展 ^Δ[J].中国药房,2023,34(05):631-635.

QIAO Tingting,ZHANG Zhihong,ZHOU Junfa,et al.Research progress on pharmacological effects of bilirubin nanoparticles[J].ZHONGGUO YAOFANG,2023,34(05):631-635.
乔婷婷,张志宏,周俊发等.胆红素纳米颗粒的药理作用研究进展 ^Δ[J].中国药房,2023,34(05):631-635. DOI： 10.6039/j.issn.1001-0408.2023.05.22.

QIAO Tingting,ZHANG Zhihong,ZHOU Junfa,et al.Research progress on pharmacological effects of bilirubin nanoparticles[J].ZHONGGUO YAOFANG,2023,34(05):631-635. DOI： 10.6039/j.issn.1001-0408.2023.05.22.

摘要

胆红素具有良好的抗炎、抗氧化和免疫调节作用，但由于其水溶性差、生物利用度低，极大地限制了临床应用。研究人员将胆红素开发成各种纳米颗粒，借助剂型优势有效消除了胆红素溶解性低的限制，使其能够最大化地发挥抗炎、抗氧化、调节免疫等药理活性。胆红素纳米颗粒在多种胃肠道疾病、肝肾疾病、皮肤疾病、自身免疫性疾病、胰岛移植以及肿瘤的靶向治疗（既可直接抗肿瘤，又可作为药物递送系统）中均具有巨大的应用潜力。对胆红素纳米制剂的研究将推动胆红素的临床应用和相关的新药研发。

Abstract

Bilirubin has good anti-inflammatory， antioxidant and immunomodulatory effects， but its poor water solubility and low bioavailability greatly limit its clinical application. Researchers have developed bilirubin into various nanoparticles， which effectively eliminate the limitation of low solubility of bilirubin with the advantage of dosage form， so that they can maximize its pharmacological activities such as anti-inflammatory， anti-oxidation and immune regulation. Bilirubin nanoparticles have great application potential in a variety of gastrointestinal diseases， liver and kidney diseases， skin diseases， autoimmune diseases， islet transplantation and targeted therapy of tumors （both as a direct anti-tumor drug and as a drug delivery system）. The study of bilirubin nanoparticles will promote the clinical application of bilirubin and the development of related new drugs.

关键词

胆红素纳米颗粒抗炎抗氧化免疫调节抗肿瘤靶向治疗

Keywords

nanoparticlesanti-inflammatoryanti-oxidationimmune regulationanti-tumortargeted therapy

references

国家药典委员会.中华人民共和国药典：一部[S].2020年版.北京：中国医药科技出版社，2020：72-73.

TRAN D T，JEONG Y Y，KIM J M，et al. The anti-inflammatory role of bilirubin on “two-hit” sepsis animal model[J]. Int J Mol Sci，2020，21（22）：8650.

STOCKER R，YAMAMOTO Y，MCDONAGH A F，et al. Bilirubin is an antioxidant of possible physiological importance[J]. Science，1987，235（4792）：1043-1046.

DU J P，YUAN Y，CHEN S Y，et al. Serum bilirubin and the risk of rheumatoid arthritis[J]. J Clin Lab Anal，2017，31（6）：e22118.

邹秦文，石岩，刘薇，等. 牛黄类药材各类成分定量检测方法研究概况[J]. 药物分析杂志，2015，35（1）：8-15.

YAO Q，JIANG X，KOU L F，et al. Pharmacological actions and therapeutic potentials of bilirubin in islet transplantation for the treatment of diabetes[J]. Pharmacol Res，2019，145：104256.

DEKKER D，DORRESTEIJN M J，WELZEN M E B， et al. Parenteral bilirubin in healthy volunteers：a reintroduction in translational research[J]. Br J Clin Pharmacol，2018，84（2）：268-279.

仲曼，胡慧慧，缪明星，等. 纳米药物制剂体内分析方法及药动学研究进展和问题策略分析[J]. 药物评价研究，2022，45（7）：1413-1425.

SIM T M，TARINI D，DHEEN S T，et al. Nanoparticle-based technology approaches to the management of neurological disorders[J]. Int J Mol Sci，2020，21（17）：6070.

KIM M J，LEE Y，JON S，et al. PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation[J]. Biomaterials，2017，133：242-252.

HUANG Z W，SHI Y N，WANG H C，et al. Protective effects of chitosan-bilirubin nanoparticles against ethanol-induced gastric ulcers[J]. Int J Nanomedicine，2021，16：8235-8250.

LEE Y，SUGIHARA K，3rdGILLILLAND M G，et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier，microbiome and immune responses in colitis[J]. Nat Mater，2020，19（1）：118-126.

LEE Y，KIM H，KANG S，et al. Bilirubin nanoparticles as a nanomedicine for anti-inflammation therapy[J]. Angew Chem Int Ed Engl，2016，55（26）：7460-7463.

JrHINDS T D，CREEDEN J F，GORDON D M，et al. Bilirubin nanoparticles reduce diet-induced hepatic steatosis，improve fat utilization，and increase plasma β-hydroxybutyrate[J]. Front Pharmacol，2020，11：594574.

KIM J Y，LEE D Y，KANG S，et al. Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury[J]. Biomaterials，2017，133：1-10.

HUANG Z W，SHI Y N，ZHAI Y Y，et al. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury[J]. J Control Release，2021，334：275-289.

JIANG X Y，YAO Q，XIA X，et al.Self-assembled nanoparticles with bilirubin/JPH203 alleviate imiquimod-induced psoriasis by reducing oxidative stress and suppressing Th17 expansion[J]. Chem Eng J，2022，431：133956.

KEUM H，KIM T W，KIM Y，et al. Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling[J]. J Control Release，2020，325：359-369.

KAMOTHI D J，KANT V，JANGIR B L，et al. Novel preparation of bilirubin-encapsulated pluronic F-127 nanoparticles as a potential biomaterial for wound healing[J]. Eur J Pharmacol，2022，919：174809.

KIM T W，KIM Y，JUNG W，et al. Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells[J]. J Control Release，2021，331：74-84.

KIM D E，LEE Y，KIM M，et al. Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma[J]. Biomaterials，2017，140：37-44.

ZHAO X，HUANG C Y，SU M L，et al. Reactive oxygen species-responsive celastrol-loaded：bilirubin nanoparticles for the treatment of rheumatoid arthritis[J]. AAPS J，2021，24（1）：14.

YAO Q，JIANG X，ZHAI Y Y，et al. Protective effects and mechanisms of bilirubin nanomedicine against acute pancreatitis[J]. J Control Release，2020，322：312-325.

YAO Q，HUANG Z W，ZHAI Y Y，et al. Localized controlled release of bilirubin from β-cyclodextrin-conjugated ε-polylysine to attenuate oxidative stress and inflammation in transplanted islets[J]. ACS Appl Mater Interfaces，2020，12（5）：5462-5475.

KEUM H，KIM D，KIM J，et al. A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis[J]. Biomaterials，2021，275：120986.

YANG Q Y，ZHOU C H，ZHAO Q，et al. Sonochemical assisted synthesis of dual functional BSA nanoparticle for the removal of excessive bilirubin and strong anti-tumor effects[J]. Mater Sci Eng C Mater Biol Appl，2019，100：688-696.

PETELIN A，JURDANA M，JENKO PRAŽNIKAR Z，et al. Serum bilirubin correlates with serum adipokines in normal weight and overweight asymptomatic adults[J]. Acta Clin Croat，2020，59（1）：19-29.

DAINICHI T，KITOH A，OTSUKA A，et al. The epithelial immune microenvironment （EIME） in atopic dermatitis and psoriasis[J]. Nat Immunol，2018，19（12）：1286-1298.

KHAN N M，PODUVAL T B. Immunomodulatory and immunotoxic effects of bilirubin：molecular mechanisms[J]. J Leukoc Biol，2011，90（5）：997-1015.

SEDLAK T W，SALEH M，HIGGINSON D S，et al. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles[J]. Proc Natl Acad Sci U S A，2009，106（13）：5171-5176.

MAISELS M J，MCDONAGH A F. Phototherapy for neonatal jaundice[J]. N Engl J Med，2008，358（9）：920-928.

LEE Y，LEE S，LEE D Y，et al. Multistimuli-responsive bilirubin nanoparticles for anticancer therapy[J]. Angew Chem Int Ed Engl，2016，55（36）：10676-10680.

LEE Y，LEE S，JON S. Biotinylated bilirubin nanoparticles as a tumor microenvironment-responsive drug deli- very system for targeted cancer therapy[J]. Adv Sci （Weinh），2018，5（6）：1800017.

YU M N，SU D Y，YANG Y Y，et al. D-T7 peptide-modified PEGylated bilirubin nanoparticles loaded with cediranib and paclitaxel for antiangiogenesis and chemotherapy of glioma[J]. ACS Appl Mater Interfaces，2019，11（1）：176-186.

SRIVASTAVA P，PALADHI A，SINGH R，et al. Targeting PD-1 in CD8+ T cells with a biomimetic bilirubin-5-fluoro-2-deoxyuridine-bovine serum albumin nanoconstruct for effective chemotherapy against experimental lymphoma[J]. Mol Pharm，2021，18（5）：2053-2065.

SHAN L L，FAN W P，WANG W W，et al. Organosilica-based hollow mesoporous bilirubin nanoparticles for antioxidation-activated self-protection and tumor-specific deoxygenation-driven synergistic therapy[J]. ACS Nano，2019，13（8）：8903-8916.

LEE D Y，KIM J Y，LEE Y，et al. Black pigment gallstone inspired platinum-chelated bilirubin nanoparticles for combined photoacoustic imaging and photothermal therapy of cancers[J]. Angew Chem Int Ed Engl，2017，56（44）：13684-13688.

SRIVASTAVA P，HIRA S K，SRIVASTAVA D N，et al. Protease-responsive targeted delivery of doxorubicin from bilirubin-BSA-capped mesoporous silica nanoparticles against colon cancer[J]. ACS Biomater Sci Eng，2017，3（12）：3376-3385.

LEE S，LEE Y，KIM H，et al. Bilirubin nanoparticle-assisted delivery of a small molecule-drug conjugate for targeted cancer therapy[J]. Biomacromolecules，2018，19（6）：2270-2277.

JAYANTI S，MORETTI R，TIRIBELLI C，et al. Bilirubin：a promising therapy for Parkinson’s disease[J]. Int J Mol Sci，2021，22（12）：6223.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

外泌体载药系统的研究进展

巨噬细胞膜仿生纳米递药系统在疾病靶向治疗中的应用

化疗联合分子靶向药物治疗三阴性乳腺癌的研究进展

分子靶向药物治疗非小细胞肺癌的策略

抗体-药物偶联物在实体瘤治疗中的临床研究进展